SPDR S&P Biotech ETF (XBI) Stock
Broad US biotech fund tracking hundreds of companies. Here's the price, business snapshot, and what's worth knowing about SPDR S&P Biotech ETF in October 2026.
The SPDR S&P Biotech ETF offers investors access to a broad selection of U.S. biotechnology companies, currently holding approximately 167 stocks. As a Health sector fund, it tracks the performance of the S&P Biotechnology Select Industry Index, which uses equal weighting to give smaller companies a greater influence compared to market-cap weighted indices. With net assets of USD 10.34 billion and an expense ratio of 0.35%, it is a substantial vehicle for sector exposure. The fund currently provides a dividend yield of 0.36%. Biotech is known for its volatility and innovation potential, meaning values can rise and fall significantly. This fund is designed for general educational purposes and does not guarantee returns, so investors should consider their risk tolerance before investing.
About This Stock
STATE STREET SPDR S&P BIOTECH ETF
XBI
Current Price
$150.76
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
XBI
Market Cap
N/A
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Dividend
STATE STREET SPDR S&P BIOTECH ETF does not pay a dividend, which may be because it is focusing on growth rather than returning money to investors. If you invested $1000 you would be paid $0 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Equal Weight Structure
Unlike market-cap funds, this ETF uses an equal-weighting method, meaning mid and small-cap firms have a larger impact on performance, though volatility can vary.
Biotech Sector Focus
It targets the health sector, specifically biotechnology companies often at the forefront of innovation. However, clinical trial results can cause significant price fluctuations.
Broad Diversification
With 167 holdings, it provides diversified exposure within a single industry. This helps spread risk across multiple companies, though sector-specific downturns may still impact all holdings.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
